KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash from Financing Activities (2016 - 2025)

Sarepta Therapeutics has reported Cash from Financing Activities over the past 15 years, most recently at -$39.2 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at -$39.2 million for Q4 2025, down 180.03% from a year ago — trailing twelve months through Dec 2025 was -$168.3 million (down 234.88% YoY), and the annual figure for FY2025 was -$168.3 million, down 234.88%.
  • Cash from Financing Activities for Q4 2025 was -$39.2 million at Sarepta Therapeutics, up from -$117.8 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for SRPT hit a ceiling of $549.2 million in Q4 2021 and a floor of -$117.8 million in Q3 2025.
  • Median Cash from Financing Activities over the past 5 years was $8.3 million (2021), compared with a mean of $43.8 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 3567.05% in 2022 and later tumbled 956.22% in 2025.
  • Sarepta Therapeutics' Cash from Financing Activities stood at $549.2 million in 2021, then crashed by 98.04% to $10.7 million in 2022, then tumbled by 81.92% to $1.9 million in 2023, then skyrocketed by 2421.41% to $49.0 million in 2024, then crashed by 180.03% to -$39.2 million in 2025.
  • The last three reported values for Cash from Financing Activities were -$39.2 million (Q4 2025), -$117.8 million (Q3 2025), and -$23.8 million (Q2 2025) per Business Quant data.